retatrutide and slu-pp-332 marketing raises concerns over safety ethics in functional medicine | Matt Kaeberlein posted on the topic SLU-PP 332 | Purity Peptides

In the SURMOUNT-1 clinical trial, patients achieved significant weight reduction over 72 weeks, with average losses ranging from 15% to 21% of initial body weight depending on the dose

More Stable Energy Levels Some individuals report feeling less fatigue on lower doses compared to higher ones

In total, the average family premium has increased annually by 7% in California, and 6% nationally

In her 2026 interviews she clarified that her 60-pound loss was achieved through a prescription GLP-1 medication that helped her body process food more effectively

Impact of semaglutide on osteoarthritis risk in patients with obesity: a retrospective cohort study

Our dedicated medical team utilizes advanced techniques and expertise to deliver exceptional care, tailored to each clients unique needs